Pádraig O'Sullivan (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

2270.To ask the Minister for Health the number of patients that could have benefitted from access to ravulizumab if positive reimbursement recommendations had been issued by the HSE for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome for these respective patient populations in 2021, 2022 and 2023, in tabular form; and if he will make a statement on the matter. [32236/24]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Pádraig O'Sullivan (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

2271.To ask the Minister for Health the potential direct savings the HSE would have realised, had positive reimbursement recommendations been issued by the HSE for ravulizumab, for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome, in each year since 2022, in tabular form; and if he will make a statement on the matter. [32237/24]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

As this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.